Related Experiment Videos
Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma
Ellen Meijer1, Pieter Sonneveld
1Department of Hematology, Erasmus University MC, Rotterdam, The Netherlands. e.meijer.2@erasmusmc.nl
Nature Reviews. Clinical Oncology
|April 25, 2009
Summary
Lenalidomide plus dexamethasone is more effective than dexamethasone alone for patients with relapsed or refractory multiple myeloma previously treated with thalidomide. This combination therapy offers improved outcomes in this patient subgroup.
Area of Science:
- Hematology
- Clinical Oncology
- Pharmacology
Background:
- Multiple myeloma is a hematologic malignancy.
- Relapsed or refractory disease poses treatment challenges.
- Prior thalidomide treatment can influence subsequent therapy efficacy.
Purpose of the Study:
- To evaluate the efficacy of lenalidomide plus dexamethasone versus dexamethasone alone.
- To analyze outcomes in patients with relapsed or refractory multiple myeloma previously treated with thalidomide.
Main Methods:
- Prospective subgroup analysis of two randomized, double-blind, placebo-controlled phase III clinical trials.
- Comparison of lenalidomide plus dexamethasone versus dexamethasone monotherapy.
Main Results:
- The combination of lenalidomide plus dexamethasone demonstrated superior efficacy compared to dexamethasone alone.
- This finding was observed in the specific subgroup of patients previously treated with thalidomide.
Conclusions:
- Lenalidomide plus dexamethasone is a superior treatment option for relapsed or refractory multiple myeloma patients with prior thalidomide exposure.
- Results support the use of this combination in clinical practice for this patient population.
